News | March 17, 2024
Sumitomo Pharma announces availability of ORGOVYX in Canada
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
WINLEVI works differently from any other topical acne treatment
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Plans to double its manufacturing footprint to bolster the growth
Subscribe To Our Newsletter & Stay Updated
